Andere Sprachen Iterum Therapeutics plc

Aktien

A3DR61

IE000TTOOBX0

ITRM

Verzögert Nasdaq Andere Börsenplätze 19:06:07 01.05.2024			% 5 Tage	% 1. Jan.
1,574 ^USD	+2,87 %		+1,54 %	-20,11 %

29.04.	Iterum Therapeutics reicht bei der US-Arzneimittelbehörde FDA erneut einen Zulassungsantrag für orales Sulopenem ein	CI
28.03.	Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	29.04.
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	29.04.
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	28.03.
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28.03.
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	21.03.
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat	15.03.
Iterum Therapeutics Provides Business Update	06.03.
Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives	06.03.
Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint	30.01.
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	30.01.
Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections	30.01.
Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023	29.12.
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule	04.12.
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Iterum Therapeutics Reports Third Quarter 2023 Financial Results	14.11.
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023	07.11.
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	24.10.23
Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	24.10.23
Iterum Therapeutics to Present Data at IDWeek 2023	12.10.23
Iterum Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	02.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Iterum Therapeutics plc

Aktien

A3DR61

IE000TTOOBX0

ITRM

Andere Sprachen

Filter